Skip to product information
1 of 1

PE-Cy7 Mouse Anti-Human HLA-DR Antibody (S-R566)

PE-Cy7 Mouse Anti-Human HLA-DR Antibody (S-R566)

Catalog Number: S0B5516 Application: FCM Reactivity: Human Conjugation: PE-Cy7 Brand: Starter
Price:
Regular price $150.00 USD
Regular price Sale price $150.00 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen HLA-DR
Synonyms HLA class II histocompatibility antigen, DR alpha chain; MHC class II antigen DRA; HLA-DRA1; HLA-DRA
Location Cell membrane, Endoplasmic reticulum membrane
Accession P01903
Clone Number S-R566
Antibody Type Mouse mAb
Isotype IgG2a
Application FCM
Reactivity Hu
Positive Sample Human PBMC
Purification Protein A
Concentration 0.2mg/ml
Conjugation PE-Cy7
Physical Appearance Liquid
Storage Buffer

PBS, 1% BSA, 0.3% Proclin 300

Stability & Storage 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied.

Dilution


application dilution species
FCM 1.25μl per million cells in 100μl volume Hu

Background

HLA-DR is a subtype of the human leukocyte antigen (HLA) complex, specifically classified as a class II molecule, and is encoded by genes located on chromosome 6. It plays a crucial role in the immune system by presenting peptide antigens to CD4+ T cells, which subsequently trigger adaptive immune responses, including the activation of B cells and the production of antibodies. HLA-DR is primarily expressed on antigen-presenting cells such as macrophages, dendritic cells, and B cells, and its expression levels can indicate the degree of immune system activation. This molecule is also significant in clinical settings, as it is associated with various autoimmune diseases (e.g., rheumatoid arthritis linked to HLA-DR4) and is a key factor in determining the success of organ transplants. Additionally, HLA-DR has been studied in the context of cancer immunotherapy, where its expression on tumor cells can influence the effectiveness of immune-mediated tumor suppression.

Picture

FC

Flow cytometric analysis of Human HLA-DR expression on human PBMC (human peripheral blood mononuclear cells). Human PBMC were stained with Brilliant Violet 421™ Mouse Anti-Human CD19 antibody and either PE-Cy7 Mouse IgG2a Isotype Control (Left panel) or SDT PE-Cy7 Mouse Anti-Human HLA-DR Antibody (Right panel) at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)